United Pharma


Concise Prescribing Info
Aspilets Secondary prevention of cerebrovascular events in transient ischemic attacks (TIA) or minor stroke; reinfarction in previous MI; restenosis of CABG; thrombosis of the arteriovenous shunts in hemodialysis. Primary prevention of pregnancy-induced HTN; preeclampsia & intrauterine growth retardation, particularly in pregnant women w/ preexisting chronic HTN; autoimmune disorders eg, SLE, positive anticardiolipin Ab test, history of recurring toxemia in successive pregnancies, HTN developing before the 20th wk of gestation. Aspilets-EC Prevention of CV diseases in men ages 45-79 yr & women 55-79 yr. Primary prevention of thromboembolic disorders & CV events, eg, ischemic stroke, TIA, acute MI, prevention of recurrent MI; unstable angina pectoris & chronic stable angina pectoris. Secondary prevention of CV disease in patients w/ DM especially in the following subgroups: History of MI, vascular bypass procedure, stroke or TIA & angina; patients w/ additional risk factors: HTN, smoking, dyslipidemia & family history of CV disease. Patients who have undergone revascularization procedures, eg, CABG, percutaneous transluminal coronary angioplasty (PTCA), & carotid endarterectomy. Primary prevention of pregnancy-induced HTN, pre-eclampsia & intrauterine growth retardation in pregnant women w/ pre-existing chronic HTN, auto-immune disorders, eg, SLE, positive cardiolipin Ab test, history of recurring toxemia in successive pregnancies & hypotension before the 20th wk of gestation.
Dosage/Direction for Use
Aspilets 1 tab once daily. High-risk pregnancy Start therapy after 1st trimester & discontinue at 37th wk of gestation. Aspilets-EC Ischemic stroke & TIA 50-325 mg once daily. Maintenance: Continue indefinitely. Prevention of recurrent MI 75-325 mg once daily. Maintenance: Continue indefinitely. Unstable & chronic stable angina pectoris 75-325 mg once daily. Maintenance: Continue indefinitely. Primary & secondary prevention of CV events in patients w/ type 1 or type 2 DM 75-325 mg once daily. Maintenance: Continue indefinitely. CABG 325 mg once daily starting 6 hr post-procedure. Maintenance: Continue for 1 yr post-procedure. PTCA 325 mg given 2 hr pre-angioplasty. Maintenance: 160-325 mg once daily. Continue indefinitely. Carotid endarterectomy 80 mg once daily to 625 mg bd starting pre-surgery. Maintenance: Continue indefinitely. Prevention of complications of pregnancy, pregnancy-induced HTN, pre-eclampsia, intrauterine growth retardation, pregnancy w/ SLE, positive cardiolipin Ab test 80 mg daily from 13th to 26th wk of gestation.
Should be taken with food.
Aspilets-EC Hypersensitivity. Patients w/ asthma, rhinitis & nasal polyps. May cause severe urticaria, angioedema or bronchospasm. Childn or teenagers w/ viral infections w/ or w/o fever.
Special Precautions
Avoid use 1 wk prior to & during labor, delivery & any surgical procedure for resulting excessive blood loss. May cause severe GI bleeding in patients ≥60 yr, w/ history of GI ulcers or bleeding problems, concomitantly using anticoagulants, steroids & other NSAID-containing medicines, in prolonged use of aspirin. Risk of bleeding in chronic & heavy alcohol consumption. Increased bleeding time in patients w/ hemophilia or acquired bleeding disorder. Do not use in severe renal failure (GFR >10 mL/minute) & severe hepatic insufficiency. Avoid use during 3rd trimester of pregnancy & during lactation.
Adverse Reactions
Fever, hypothermia, thirst; dysrhythmias, hypotension, tachycardia; dehydration, hyperkalemia, metabolic acidosis, resp alkalosis; dyspepsia, GI bleeding, ulceration & perforation, nausea, vomiting, transient elevations of hepatic enzymes, hepatitis, Reye’s syndrome, pancreatitis; prolongation of prothrombin time, disseminated intravascular coagulation, coagulopathy, thrombocytopenia; acute anaphylaxis, angioedema, asthma, bronchospasm, laryngeal edema, urticaria; hypoglycemia in childn, hyperglycemia; rhabdomyolysis; agitation, cerebral edema, coma, confusion, dizziness, headache, subdural or intracranial hemorrhage, lethargy, seizures; prolonged pregnancy & labor, stillbirths, low birth wt infants, antepartum & postpartum bleeding; hyperpnea, pulmonary edema, tachypnea; hearing loss, tinnitus; interstitial nephritis, papillary necrosis, proteinuria, renal insufficiency & failure.
Drug Interactions
May diminish hyponatremic & hypotensive effects of ACE inhibitors. Increased serum conc & toxicity of acetazolamide. Decreased phenytoin total conc. Increased serum valproic acid levels. Diminished hypotensive effects of β-blockers. Diminished diuretic effects in patients w/ underlying renal or CV disease. Inhibits renal clearance of methotrexate leading to bone marrow toxicity. Avoid concurrent use w/ other NSAIDs, heparin & warfarin, due to increased risk of bleeding. Antagonizes uricosuric action of probenecid & sulfinpyrazone. Increased effectiveness of oral hypoglycemic drugs.
ATC Classification
B01AC06 - acetylsalicylic acid ; Belongs to the class of platelet aggregation inhibitors excluding heparin. Used in the treatment of thrombosis.
Aspilets tab 80 mg
Aspilets-EC tab 80 mg
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in